VR Logo

Legend Biotech Corporations (LEGN) download report


Healthcare | Biotechnology & Pharma Research

Legend Biotech Corporations (LEGN) Premium Coverage

52 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally.

IPO Date: 05-Jun-2020

CEO & Director: Dr. Ying Huang Ph.D.

Chief Financial Officer: Ms. Lori A. Macomber CPA

Listing: NASDAQ: LEGN

Country: United States

Headquarters: Somerset, NJ

Website: https://www.legendbiotech.com

Key Facts

Market cap: $8,152.49 Mln

Revenue (TTM): $116.94 Mln

Earnings (TTM): $-345.76 Mln

Cash: $791.26 Mln

Total Debt: $0.00 Mln

Insider's Holding: 1.46%

Liquidity: Low

52 Week range: $30.76 - 58.00

Shares outstanding: 154,228,000

5 Years Aggregate:

  • CFO: $-199.23 Mln
  • EBITDA: $-807.54 Mln
  • Net Profit: $-816.08 Mln

Stock Performance

Time Period Legend Biotech Corporations (LEGN) S&P BSE Sensex* S&P Midcap 400*
YTD12.72-8.71-17.59
1 month33.52-3.11-5.68
3 months42.46-7.30-13.66
1 Year30.990.48-14.10
3 Years--10.347.25
5 Years--11.435.99
10 Years--12.109.97
As on 27-Jun-2022 *As on 28-Jun-2022
Year Legend Biotech Corporations (LEGN) S&P Midcap 400 S&P BSE Sensex
202165.5223.2121.99